Taselisib

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials were continued for patients exhibiting benefit.

Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials were continued for patients exhibiting benefit.

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1332224345 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.